These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1511564)

  • 41. Pancreatic beta-cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal.
    Marchesini G; Melli A; Checchia GA; Mattioli L; Capelli M; Cassarani S; Zoli M; Pisi E
    Metabolism; 1985 Aug; 34(8):695-701. PubMed ID: 3894876
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship between beta-cell responsiveness and fasting plasma glucose in Caucasian subjects with newly presenting type 2 diabetes.
    Hovorka R; Albarrak A; Chassin L; Luzio SD; Playle R; Owens DR
    Diabet Med; 2001 Oct; 18(10):797-802. PubMed ID: 11678969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
    Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S
    N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The beta-cell response to glucagon and mixed meal stimulation in non-insulin dependent diabetes.
    Gjessing HJ; Damsgaard EM; Matzen LE; Faber OK; Frøland A
    Scand J Clin Lab Invest; 1988 Dec; 48(8):771-7. PubMed ID: 3070718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beta-cell dysfunction in hyperglycaemic rat models: recovery of glucose-induced insulin secretion with lowering of the ambient glucose level.
    Leahy JL; Weir GC
    Diabetologia; 1991 Sep; 34(9):640-7. PubMed ID: 1955096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Loss of early insulin secretion leads to postprandial hyperglycaemia.
    Del Prato S
    Diabetologia; 2003 Mar; 46 Suppl 1():M2-8. PubMed ID: 12652352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes.
    Gjessing HJ; Matzen LE; Faber OK; Frøland A
    Diabetologia; 1989 May; 32(5):305-11. PubMed ID: 2666217
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impaired insulin secretion and increased insulin sensitivity in familial maturity-onset diabetes of the young 4 (insulin promoter factor 1 gene).
    Clocquet AR; Egan JM; Stoffers DA; Muller DC; Wideman L; Chin GA; Clarke WL; Hanks JB; Habener JF; Elahi D
    Diabetes; 2000 Nov; 49(11):1856-64. PubMed ID: 11078452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reproducibility of beta-cell function estimates in non-insulin-dependent diabetes mellitus.
    Gjessing HJ; Damsgaard EM; Matzen LE; Frøland A; Faber OK
    Diabetes Care; 1987; 10(5):558-62. PubMed ID: 3315512
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells.
    Hamaguchi T; Fukushima H; Uehara M; Wada S; Shirotani T; Kishikawa H; Ichinose K; Yamaguchi K; Shichiri M
    Diabetologia; 1991 Nov; 34(11):801-6. PubMed ID: 1769438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.
    Cozma LS; Luzio SD; Dunseath GJ; Underwood PM; Owens DR
    Diabetes Care; 2005 May; 28(5):1001-7. PubMed ID: 15855557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secretion and hepatic extraction of insulin after weight loss in obese noninsulin-dependent diabetes mellitus.
    Henry RR; Brechtel G; Griver K
    J Clin Endocrinol Metab; 1988 May; 66(5):979-86. PubMed ID: 3283164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (non-insulin-dependent) diabetic subjects.
    Levy JC; Rudenski A; Burnett M; Knight R; Matthews DR; Turner RC
    Diabetologia; 1991 Jul; 34(7):488-99. PubMed ID: 1916054
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes.
    Brown RJ; Sinaii N; Rother KI
    Diabetes Care; 2008 Jul; 31(7):1403-4. PubMed ID: 18594062
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abnormal glucose modulation of islet A- and B-cell responses to arginine in non-insulin-dependent diabetes mellitus.
    Dimitriadis GD; Pehling GB; Gerich JE
    Diabetes; 1985 Jun; 34(6):541-7. PubMed ID: 3891467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C.
    Tai TY; Lu JY; Chen CL; Lai MY; Chen PJ; Kao JH; Lee CZ; Lee HS; Chuang LM; Jeng YM
    J Endocrinol; 2003 Sep; 178(3):457-65. PubMed ID: 12967337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.